Paeoniflorin inhibits hepatocellular carcinoma growth by reducing PD-L1 expression
Abnormal expression of programmed death-ligand 1 (PD-L1) on cancer cells contributes to immune escape in hepatocellular carcinoma (HCC). Paeoniflorin has been shown to inhibit the growth of HCC; however, whether its inhibitory effect involves reducing PD-L1 expression on HCC cells remains unknown. W...
Main Authors: | Meng Gao, Dongjian Zhang, Cuihua Jiang, Qiaomei Jin, Jian Zhang |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2023-10-01
|
Series: | Biomedicine & Pharmacotherapy |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S0753332223011083 |
Similar Items
-
Paeoniflorin increases the anti-tumor efficacy of sorafenib in tumor-bearing mice with liver cancer via suppressing the NF-κb/PD-l1 axis
by: Junfei Li, et al.
Published: (2024-01-01) -
HAMP as a Potential Diagnostic, PD-(L)1 Immunotherapy Sensitivity and Prognostic Biomarker in Hepatocellular Carcinoma
by: Guoming Chen, et al.
Published: (2023-02-01) -
PD-1/PD-L1 checkpoint inhibitors in advanced hepatocellular carcinoma immunotherapy
by: Qian Li, et al.
Published: (2022-12-01) -
Nifuroxazide suppresses PD-L1 expression and enhances the efficacy of radiotherapy in hepatocellular carcinoma
by: Tiesuo Zhao, et al.
Published: (2024-03-01) -
Predictive Factors for Response to PD-1/PD-L1 Checkpoint Inhibition in the Field of Hepatocellular Carcinoma: Current Status and Challenges
by: Zuzana Macek Jilkova, et al.
Published: (2019-10-01)